Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.
2023 Help me understand this report
Klarzelliges Nierenzellkarzinom
Abstract: Das 5-Jahres-Update der Studie KEYNOTE-426 untermauert die Überlegenheit der Kombination Pembrolizumab plus Axitinib im Vergleich zu Sunitinib in der Erstlinientherapie von Patienten mit klarzelligem Nierenzellkarzinom (ccRCC).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
